Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis

Cancer Letters

Volumn 346, Issue 1, 2014, Pages 6-16

  Ji, Rui Cheng ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

HIF 1 ; Hypoxia; Lymphangiogenesis; Lymphatic endothelial cells; Tumor metastasis; VEGF A C D

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

CD4+ T LYMPHOCYTE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPOXIA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MACROPHAGE; METASTASIS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE PRESSURE; TRANSCRIPTION INITIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION;

HIF-1Α; HYPOXIA; LYMPHANGIOGENESIS; LYMPHATIC ENDOTHELIAL CELLS; TUMOR METASTASIS; VEGF-A/-C/-D;

ANIMALS; CELL HYPOXIA; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; TUMOR MICROENVIRONMENT;

EID: 84896700519     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.001     Document Type: Review

References (144)

1. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
2. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
3. Lunt S.J., Chaudary N., Hill R.P. The tumor microenvironment and metastatic disease. Clin. Exp. Metastas. 2009, 26:19-34.
4. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., Rowan A., Yan Z., Campochiaro P.A., Semenza G.L. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 2003, 93:1074-1081.
5. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 2007, 74:72-84.
6. Eyries M., Siegfried G., Ciumas M., Montagne K., Agrapart M., Lebrin F., Soubrier F. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ. Res. 2008, 103:432-440.
7. Foskett A.M., Ezekiel U.R., Trzeciakowski J.P., Zawieja D.C., Muthuchamy M. Hypoxia and extracellular matrix proteins influence angiogenesis and lymphangiogenesis in mouse embryoid bodies. Front Physiol. 2011, 2:103.
8. Lahat N., Bitterman H., Engelmayer-Goren M., Rosenzweig D., Weiss-Cerem L., Rahat M.A. Reduced TIMP-2 in hypoxia enhances angiogenesis. Am. J. Physiol. Cell Physiol. 2011, 300:C557-566.
9. Okada K., Osaki M., Araki K., Ishiguro K., Ito H., Ohgi S. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res. 2005, 25(4):3003-3009.
10. Schoppmann S.F., Fenzl A., Schindl M., Bachleitner-Hofmann T., Nagy K., Gnant M., Horvat R., Jakesz R., Birner P. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res. Treat. 2006, 99:135-141.
11. Simiantonaki N., Jayasinghe C., Michel-Schmidt R., Peters K., Hermanns M.I., Kirkpatrick C.J. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int. J. Oncol. 2008, 32:585-592.
12. Zampell J.C., Yan A., Avraham T., Daluvoy S., Weitman E.S., Mehrara B.J. HIF-1α coordinates lymphangiogenesis during wound healing and in response to inflammation. FASEB J. 2012, 26:1027-1039.
13. Semenza G.L. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013, 32:4057-4063.
14. Sullivan R., Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastas. Rev. 2007, 26:319-331.
15. McColl B.K., Stacker S.A., Achen M.G. Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 2004, 112:463-480.
16. Faller D.V. Endothelial cell responses to hypoxic stress. Clin. Exp. Pharmacol. Physiol. 1999, 26:74-84.
17. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
18. Mawji I.A., Marsden P.A. Perturbations in paracrine control of the circulation: role of the endothelial-derived vasomediators, endothelin-1 and nitric oxide. Microsc. Res. Tech. 2003, 60:46-58.
19. Marchetti C., Casasco A., Di Nucci A., Reguzzoni M., Rosso S., Piovella F., Calligaro A., Polak J.M. Endothelin and nitric oxide synthase in lymphatic endothelial cells: immunolocalization in vivo and in vitro. Anat. Rec. 1997, 248:490-497.
20. Doboszyńska T., Andronowska A., Modzelewska B. Endothelin-1 and endothelial nitric oxide synthase immunoreactivity in lymphatic vessels of the uterine broad ligament during the estrous cycle in the pig. Cells Tissues Organs. 2002, 171:152-161.
21. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 2013, 31:2205-2218.
22. Spinella F., Garrafa E., Di Castro V., Rosanò L., Nicotra M.R., Caruso A., Natali P.G., Bagnato A. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009, 69:2669-2676.
23. Michiels C., Arnould T., Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim. Biophys. Acta 2000, 1497(1):1-10.
24. Nilsson I., Shibuya M., Wennström S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp. Cell Res. 2004, 299:476-485.
25. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
26. Cao R., Eriksson A., Kubo H., Alitalo K., Cao Y., Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ. Res. 2004, 94:664-670.
27. Ji R.C. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol. Histopathol. 2009, 24:377-384.
28. Mikhaylova M., Mori N., Wildes F.B., Walczak P., Gimi B., Bhujwalla Z.M. Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 2008, 10:380-389.
29. Branco-Price C., Zhang N., Schnelle M., Evans C., Katschinski D.M., Liao D., Ellies L., Johnson R.S. Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell 2012, 21:52-65.
30. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., Johnson R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.
31. Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J. Heart Lung Transplant. 1999, 18:1041-1053.
32. Kotch L.E., Iyer N.V., Laughner E., Semenza G.L. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev. Biol. 1999, 209:254-267.
33. Schito L., Rey S., Tafani M., Zhang H., Wong C.C., Russo A., Russo M.A., Semenza G.L. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. USA 2012, 109:E2707-2716.
34. Min Y., Ghose S., Boelte K., Li J., Yang L., Lin P.C. C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α. Oncogene 2011, 30:4901-4909.
35. Zhou B., Si W., Su Z., Deng W., Tu X., Wang Q. Transcriptional activation of the Prox1 gene by HIF-1α and HIF-2α in response to hypoxia. FEBS Lett. 2013, 587:724-731.
36. An S.S., Pennella C.M., Gonnabathula A., Chen J., Wang N., Gaestel M., Hassoun P.M., Fredberg J.J., Kayyali U.S. Hypoxia alters biophysical properties of endothelial cells via p38 MAPK- and Rho kinase-dependent pathways. Am. J. Physiol. Cell Physiol. 2005, 289:C521-530.
37. Irigoyen M., Ansó E., Martínez E., Garayoa M., Martínez-Irujo J.J., Rouzaut A. Hypoxia alters the adhesive properties of lymphatic endothelial cells, A transcriptional and functional study. Biochim. Biophys. Acta 2007, 1773:880-890.
38. Irigoyen M., Ansó E., Salvo E., Dotor De Las Herrerías J., Martínez-Irujo J.J., Rouzaut A. TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions. Cell Mol. Life Sci. 2008, 65:2244-2255.
39. Mizukami Y., Kohgo Y., Chung D.C. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res. 2007, 13:5670-5674.
40. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
41. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
42. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9:677-684.
43. Tanaka H., Yamamoto M., Hashimoto N., Miyakoshi M., Tamakawa S., Yoshie M., Tokusashi Y., Yokoyama K., Yaginuma Y., Ogawa K. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res. 2006, 66:11263-11270.
44. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
45. Patel N., Kalra V.K. Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells. J. Biol. Chem. 2010, 285:20570-20579.
46. Mabjeesh N.J., Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol. Histopathol. 2007, 22:559-572.
47. Kizaka-Kondoh S., Kuchimaru T., Kadonosono T. Pathophysiological response to hypoxia-from the molecular mechanisms of malady to drug discovery: hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy. J. Pharmacol. Sci. 2011, 115:440-445.
48. Trebec-Reynolds D.P., Voronov I., Heersche J.N., Manolson M.F. VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha. J. Cell Biochem. 2010, 110:343-351.
49. Medici D., Olsen B.R. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS ONE 2012, 7:e42913.
50. Ny A., Koch M., Vandevelde W., Schneider M., Fischer C., Diez-Juan A., Neven E., Geudens I., Maity S., Moons L., Plaisance S., Lambrechts D., Carmeliet P., Dewerchin M. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood 2008, 112:1740-1749.
51. Hägerling R., Pollmann C., Andreas M., Schmidt C., Nurmi H., Adams R.H., Alitalo K., Andresen V., Schulte-Merker S., Kiefer F. A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy. EMBO J. 2013, 32:629-644.
52. Simons M., Eichmann A. Physiology. Lymphatics are in my veins. Science 2013, 341:622-624.
53. Lee A.S., Lee J.E., Jung Y.J., Kim D.H., Kang K.P., Lee S., Park S.K., Lee S.Y., Kang M.J., Moon W.S., Kim H.J., Jeong Y.B., Sung M.J., Kim W. Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction. Kidney Int. 2013, 83:50-62.
54. Kreuger J., Nilsson I., Kerjaschki D., Petrova T., Alitalo K., Claesson-Welsh L. Early lymph vessel development from embryonic stem cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1073-1078.
55. Bridges J.P., Lin S., Ikegami M., Shannon J.M. Conditional hypoxia inducible factor-1α induction in embryonic pulmonary epithelium impairs maturation and augments lymphangiogenesis. Dev. Biol. 2012, 362:24-41.
56. Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12:9-22.
57. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.
58. Coso S., Zeng Y., Opeskin K., Williams E.D. Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS ONE 2012, 7:e39558.
59. Yoo Y.A., Kang M.H., Lee H.J., Kim B.H., Park J.K., Kim H.K., Kim J.S., Oh S.C. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011, 71:7061-7070.
60. Lee S.H., Lee Y.J., Han H.J. Role of hypoxia-induced fibronectin-integrin β1 expression in embryonic stem cell proliferation and migration: involvement of PI3K/Akt and FAK. J. Cell Physiol. 2011, 226:484-493.
61. Patel V., Marsh C.A., Dorsam R.T., Mikelis C.M., Masedunskas A., Amornphimoltham P., Nathan C.A., Singh B., Weigert R., Molinolo A.A., Gutkind J.S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011, 71:7103-7112.
62. Michiels C., Minet E., Michel G., Mottet D., Piret J.P., Raes M. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 2001, 52:49-53.
63. Minet E., Michel G., Mottet D., Piret J.P., Barbieux A., Raes M., Michiels C. C-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp. Cell Res. 2001, 265:114-124.
64. Ming J., Zhang Q., Qiu X., Wang E. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. Eur. J. Cancer 2009, 45:866-873.
65. Lopez-Bergami P., Lau E., Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer 2010, 10:65-76.
66. van Uden P., Kenneth N.S., Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem. J. 2008, 412:477-484.
67. Flister M.J., Wilber A., Hall K.L., Iwata C., Miyazono K., Nisato R.E., Pepper M.S., Zawieja D.C., Ran S. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 2010, 115:418-429.
68. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
69. von Lueder T.G., Kjekshus H., Edvardsen T., ØIe E., Urheim S., Vinge L.E., Ahmed M.S., Smiseth O.A., Attramadal H. Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1. Cardiovasc. Res. 2004, 63:41-50.
70. Nelson J., Bagnato A., Battistini B., Nisen P. The endothelin axis: emerging role in cancer. Nat. Rev. Cancer 2003, 3:110-116.
71. Zhuo W., Jia L., Song N., Lu X.A., Ding Y., Wang X., Song X., Fu Y., Luo Y. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis. Clin. Cancer Res. 2012, 18:5387-5398.
72. Nakayama M., Takahashi K., Murakami O., Shirato K., Shibahara S. Induction of adrenomedullin by hypoxia in cultured human coronary artery endothelial cells. Peptides 1999, 20:769-772.
73. Maybin J.A., Battersby S., Hirani N., Nikitenko L.L., Critchley H.O., Jabbour H.N. The expression and regulation of adrenomedullin in the human endometrium: a candidate for endometrial repair. Endocrinology 2011, 152:2845-2856.
74. Elbarghati L., Murdoch C., Lewis C.E. Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology 2008, 213:899-908.
75. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
76. Lewis J.S., Landers R.J., Underwood J.C., Harris A.L., Lewis C.E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 2000, 192:150-158.
77. Burke B., Tang N., Corke K.P., Tazzyman D., Ameri K., Wells M., Lewis C.E. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol. 2002, 196:204-212.
78. Murdoch C., Muthana M., Lewis C.E. Hypoxia regulates macrophage functions in inflammation. J. Immunol. 2005, 175:6257-6263.
79. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin Invest. 2004, 113:1040-1050.
80. Ji R.C. Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis. Cell Mol. Life Sci. 2012, 69:897-914.
81. Shimoyamada H., Yazawa T., Sato H., Okudela K., Ishii J., Sakaeda M., Kashiwagi K., Suzuki T., Mitsui H., Woo T., Tajiri M., Ohmori T., Ogura T., Masuda M., Oshiro H., Kitamura H. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am. J. Pathol. 2010, 177:70-83.
82. Larsen M., Tazzyman S., Lund E.L., Junker N., Lewis C.E., Kristjansen P.E., Murdoch C. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Lett. 2008, 265:239-249.
83. Gaber T., Schellmann S., Erekul K.B., Fangradt M., Tykwinska K., Hahne M., Maschmeyer P., Wagegg M., Stahn C., Kolar P., Dziurla R., Löhning M., Burmester G.R., Buttgereit F. Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia. J. Immunol. 2011, 186:764-774.
84. Das S., Sarrou E., Podgrabinska S., Cassella M., Mungamuri S.K., Feirt N., Gordon R., Nagi C.S., Wang Y., Entenberg D., Condeelis J., Skobe M. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J. Exp. Med. 2013, 210:1509-1528.
85. Jung Y.J., Isaacs J.S., Lee S., Trepel J., Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003, 17:2115-2117.
86. Frede S., Freitag P., Otto T., Heilmaier C., Fandrey J. The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation. Cancer Res. 2005, 65:4690-4697.
87. Baluk P., Hogmalm A., Bry M., Alitalo K., Bry K., McDonald D.M. Transgenic overexpression of interleukin-1β induces persistent lymphangiogenesis but not angiogenesis in mouse airways. Am. J. Pathol. 2013, 182:1434-1447.
88. Nakao S., Noda K., Zandi S., Sun D., Taher M., Schering A., Xie F., Mashima Y., Hafezi-Moghadam A. VAP-1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis. Am. J. Pathol. 2011, 178:1913-1921.
89. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top Microbiol. Immunol. 1999, 237:97-132.
90. Ji R.C. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastas. Rev. 2006, 25:677-694.
91. Rofstad E.K., Ruud E.B., Mathiesen B., Galappathi K. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin. Cancer Res. 2010, 16:936-945.
92. Leu A.J., Berk D.A., Lymboussaki A., Alitalo K., Jain R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000, 60:4324-4327.
93. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., Munn L.L., Jain R.K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
94. Sen A., Capitano M.L., Spernyak J.A., Schueckler J.T., Thomas S., Singh A.K., Evans S.S., Hylander B.L., Repasky E.A. Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. Cancer Res. 2011, 71:3872-3880.
95. Curran C.S., Keely P.J. Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition. Matrix Biol. 2013, 32:95-105.
96. James J.M., Nalbandian A., Mukouyama Y.S. TGFβ signaling is required for sprouting lymphangiogenesis during lymphatic network development in the skin. Development 2013, 140:3903-3914.
97. Kinashi H., Ito Y., Mizuno M., Suzuki Y., Terabayashi T., Nagura F., Hattori R., Matsukawa Y., Mizuno T., Noda Y., Nishimura H., Nishio R., Maruyama S., Imai E., Matsuo S., Takei Y. TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J. Am. Soc. Nephrol. 2013, 24:1627-1642.
98. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
99. Hanna S.C., Krishnan B., Bailey S.T., Moschos S.J., Kuan P.F., Shimamura T., Osborne L.D., Siegel M.B., Duncan L.M., O'Brien E.T., Superfine R., Miller C.R., Simon M.C., Wong K.K., Kim W.Y. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J. Clin. Invest. 2013, 123:2078-2093.
100. Ji R.C. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat. Res. Biol. 2006, 4:83-100.
101. Rahat M.A., Marom B., Bitterman H., Weiss-Cerem L., Kinarty A., Lahat N. Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association. J. Leukoc Biol. 2006, 79:706-718.
102. Detry B., Erpicum C., Paupert J., Blacher S., Maillard C., Bruyère F., Pendeville H., Remacle T., Lambert V., Balsat C., Ormenese S., Lamaye F., Janssens E., Moons L., Cataldo D., Kridelka F., Carmeliet P., Thiry M., Foidart J.M., Struman I., Noël A. Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 2012, 119:5048-5056.
103. Ingvarsen S., Porse A., Erpicum C., Maertens L., Jürgensen H.J., Madsen D.H., Melander M.C., Gårdsvoll H., Høyer-Hansen G., Noel A., Holmbeck K., Engelholm L.H., Behrendt N. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J. Biol. Chem. 2013, 288:10195-10204.
104. Xiang Z.L., Zeng Z.C., Fan J., Tang Z.Y., Zeng H.Y., Gao D.M. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin. Cancer Res. 2011, 17:5463-5472.
105. Talmadge J.E., Fidler I.J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010, 70:5649-5669.
106. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
107. Chen H.H., Su W.C., Lin P.W., Guo H.R., Lee W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res. Treat. 2007, 103:167-175.
108. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60:4693-4696.
109. Fujimoto J., Alam S.M., Jahan I., Sato E., Toyoki H., Hong B.L., Sakaguchi H., Tamaya T. Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer. Cancer Sci. 2006, 97:861-867.
110. Wu Y., Jin M., Xu H., Shimin Z., He S., Wang L., Zhang Y. Clinicopathologic significance of HIF-1α, CXCR4, and VEGF expression in colon cancer. Clin. Dev. Immunol. 2010, 2010:1-10.
111. Kuwai T., Kitadai Y., Tanaka S., Onogawa S., Matsutani N., Kaio E., Ito M., Chayama K. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int. J. Cancer 2003, 105:176-181.
112. Kurokawa T., Miyamoto M., Kato K., Cho Y., Kawarada Y., Hida Y., Shinohara T., Itoh T., Okushiba S., Kondo S., Katoh H. Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br. J. Cancer 2003, 89:1042-1047.
113. Katsuta M., Miyashita M., Makino H., Nomura T., Shinji S., Yamashita K., Tajiri T., Kudo M., Ishiwata T., Naito Z. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp. Mol. Pathol. 2005, 78:123-130.
114. Batmunkh E., Shimada M., Morine Y., Imura S., Kanemura H., Arakawa Y., Hanaoka J., Kanamoto M., Sugimoto K., Nishi M. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int. J. Clin. Oncol. 2010, 15:59-64.
115. Sumiyoshi Y., Kakeji Y., Egashira A., Mizokami K., Orita H., Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin. Cancer Res. 2006, 12:5112-5117.
116. Enatsu S., Iwasaki A., Shirakusa T., Hamasaki M., Nabeshima K., Iwasaki H., Kuroki M., Kuroki M. Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur. J. Cardiothorac Surg. 2006, 29:891-895.
117. Koperek O., Bergner O., Pichlhöfer B., Oberndorfer F., Hainfellner J.A., Kaserer K., Horvat R., Harris A.L., Niederle B., Birner P. Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene. J. Pathol. 2011, 225:63-72.
118. Shou Z., Lin L., Liang J., Li J.L., Chen H.Y. Expression and prognosis of FOXO3a and HIF-1α in nasopharyngeal carcinoma. J. Cancer Res. Clin. Oncol. 2012, 138:585-593.
119. Liang X., Yang D., Hu J., Hao X., Gao J., Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2008, 28:1659-1666.
120. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 2007, 14:2600-2607.
121. Cho H.J., Jung J.I., Lim D.Y., Kwon G.T., Her S., Park J.H., Park J.H. Bone marrow-derived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model. Breast Cancer Res. 2012, 14:R81.
122. Chaudary N., Milosevic M., Hill R.P. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer. Gynecol. Oncol. 2011, 123:393-400.
123. Matsumoto G., Yajima N., Saito H., Nakagami H., Omi Y., Lee U., Kaneda Y. Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma. Clin. Exp. Metastas. 2010, 27:539-547.
124. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
125. Yano A., Fujii Y., Iwai A., Kawakami S., Kageyama Y., Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin. Cancer Res. 2006, 12:6012-6017.
126. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
127. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 2010, 16:5928-5935.
128. Stohrer M., Boucher Y., Stangassinger M., Jain R.K. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60:4251-4255.
129. Ji R.C., Eshita Y., Kato S. Investigation of intratumoural and peritumoural lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours. Int. J. Exp. Pathol. 2007, 88:257-270.
130. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
131. Subarsky P., Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastas. 2003, 20:237-250.
132. Sennino B., Ishiguro-Oonuma T., Schriver B.J., Christensen J.G., McDonald D.M. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 2013, 73:3692-3703.
133. Oashi K., Furukawa H., Nishihara H., Ozaki M., Oyama A., Funayama E., Hayashi T., Kuge Y., Yamamoto Y. Pathophysiological characteristics of melanoma in-transit metastasis in a lymphedema mouse model. J. Invest Dermatol. 2013, 133:537-544.
134. Liao D., Corle C., Seagroves T.N., Johnson R.S. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007, 67:563-572.
135. Sanford D.E., Belt B.A., Panni R.Z., Mayer A., Deshpande A.D., Carpenter D., Mitchem J.B., Plambeck-Suess S.M., Worley L.A., Goetz B.D., Wang-Gillam A., Eberlein T.J., Denardo D.G., Goedegebuure S.P., Linehan D.C. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 2013, 19:3404-3415.
136. Cueni L.N., Hegyi I., Shin J.W., Albinger-Hegyi A., Gruber S., Kunstfeld R., Moch H., Detmar M. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am. J. Pathol. 2010, 177:1004-1016.
137. Hagemann T., Binder C., Binder L., Pukrop T., Trümper L., Grimshaw M.J. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol. 2005, 24:766-776.
138. Hu Y., Liu J., Huang H. Recent agents targeting HIF-1α for cancer therapy. J. Cell Biochem. 2013, 114:498-509.
139. Leppänen V.M., Tvorogov D., Kisko K., Prota A.E., Jeltsch M., Anisimov A., Markovic-Mueller S., Stuttfeld E., Goldie K.N., Ballmer-Hofer K., Alitalo K. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc. Natl. Acad. Sci. USA 2013, 110:12960-12965.
140. Suzuki K., Kadota K., Sima C.S., Nitadori J., Rusch V.W., Travis W.D., Sadelain M., Adusumilli P.S. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J. Clin. Oncol. 2013, 31:490-498.
141. Yoo Y.G., Kong G., Lee M.O. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 2006, 25:1231-1241.
142. Lee M.H., Na H., Kim E.J., Lee H.W., Lee M.O. Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1. Oncogene 2012, 31:5099-5107.
143. Du B., Yang Z.Y., Zhong X.Y., Fang M., Yan Y.R., Qi G.L., Pan Y.L., Zhou X.L. Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer. World J. Gastroenterol. 2011, 17:1219-1226.
144. Rosanò L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2013, 13:637-651.